key: cord-0816305-x4w1c9ex
authors: Gong, Jiao; Ou, Jingyi; Qiu, Xueping; Jie, Yusheng; Chen, Yaqiong; Yuan, Lianxiong; Cao, Jing; Tan, Mingkai; Xu, Wenxiong; Zheng, Fang; Shi, Yaling; Hu, Bo
title: A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China
date: 2020-04-16
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa443
sha: 80ca443bf2607ba42c7cd70ec31ec918d2feb9fd
doc_id: 816305
cord_uid: x4w1c9ex

BACKGROUND: Due to no reliable risk stratification tool for severe coronavirus disease 2019 (COVID-19) patients at admission, we aimed to construct an effective model for early identification of cases at high risk of progression to severe COVID-19. METHODS: In this retrospective three-centers study, 372 non-severe COVID-19 patients during hospitalization were followed for more than 15 days after admission. Patients who deteriorated to severe or critical COVID-19 and patients who kept non-severe state were assigned to the severe and non-severe group, respectively. Based on baseline data of the two groups, we constructed a risk prediction nomogram for severe COVID-19 and evaluated its performance. RESULTS: The training cohort consisted of 189 patients, while the two independent validation cohorts consisted of 165 and 18 patients. Among all cases, 72 (19.35%) patients developed severe COVID-19. We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19. We generated the nomogram for early identifying severe COVID-19 in the training cohort (AUC 0.912 [95% CI 0.846-0.978], sensitivity 85.71%, specificity 87.58%); in validation cohort (0.853 [0.790-0.916], 77.5%, 78.4%). The calibration curve for probability of severe COVID-19 showed optimal agreement between prediction by nomogram and actual observation. Decision curve and clinical impact curve analysis indicated that nomogram conferred high clinical net benefit. CONCLUSION: Our nomogram could help clinicians to early identify patients who will exacerbate to severe COVID-19, which will enable better centralized management and early treatment of severe patients.

Since the outbreak of novel coronavirus pneumonia in December 2019, the number of reported cases has surpassed 260,000 with over 11180 deaths worldwide, as of March 22 2020.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of coronaviruses known to cause common colds and severe illnesses such as, is the cause of COVID-19 [1].

Compared with much higher overall case-fatality rates (CFR) for the severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS), COVID-19 is responsible for more total deaths because of the increased transmission speed and the growing numbers of cases [2] . Up to now, the World Health Organization (WHO) has raised global Coronavirus Disease (COVID-19) outbreak risk to "Very High", and SARS-CoV-2 infection has become a serious threat to public health.

According to a report recently released by the Chinese Center for Disease Control and Prevention (CDC) that included approximately 44,500 confirmed cases of SARS-CoV-2 infections, up to 15.8% were severe or critical. Most COVID-19 patients have a mild disease course, while some patients experience rapid deterioration (particularly within 7-14 days) from onset of symptoms into severe COVID-19 with or without acute respiratory distress syndrome (ARDS) [3] .

Current epidemiological data suggests that the mortality rate of severe COVID-19 patients is about 20 times higher than that of non-severe COVID-19 patients [4, 5] . This situation highlights the need to identify COVID-19 patients at risk of approaching to severe COVID-19. These severe illness patients often require utilization of intensive medical resources. Therefore, early identification of patients at high risk for progression to severe COVID-19 will facilitate appropriate supportive care and reduce the mortality rate, unnecessary or inappropriate healthcare A c c e p t e d M a n u s c r i p t utilization via patient prioritization.

At present, an early warning model for predicting COVID-19 patients at-risk of developing a costly condition is scarce [3, 6] . So far, prognosis factors of COVID-19 mainly focus on the immune cells. In our study, we found that older age, higher lactate dehydrogenase (LDH) and C-reactive protein (CRP), RDW (the coefficient of variation of red blood cell distribution width), DBIL (direct bilirubin), blood urea nitrogen (BUN), and lower albumin (ALB) on admission correlated with higher odds of severe COVID-19. Based on these indexes, we developed and validated an effective prognostic nomogram with high sensitivity and specificity for accurate individualized assessment of the incidence of severe COVID-19. Among these indexes, the prognostic role of RDW in COVID-19 is underestimated, which is associated with the increased turnover of erythrocytes. Our results hinted that the turnover of RBC might be involved in severe illness. Of all potential predictors in the dataset, 0.09 % of the fields had missing values. Predictor exclusion was limited to those with more than 7% missing rate to minimize the bias of the regression coefficient. [16] . Little's MCAR test (R package BaylorEdPsych) was used to assess the suitability of the remaining missing values for imputation. This test is used to test whether missing values are "missing completely at random" (MCAR) or biased. The missing values were imputed by expectation-maximization (EM) method using SPSS statistical software, version 25 (SPSS, Inc., Chicago, IL, USA).

To identify the relative importance of each feature, feature selection was performed using the least absolute shrinkage and selection operator (LASSO) regression method, and prediction models were built using logistic regression, decision tree, random forest (RF) and support vector machine (SVM) using R package Caret, using 300-time repeated random sub-sampling validation for diverse parameter conditions, respectively. As described previously, Nomograms were established with the rms package and the performance of nomogram was evaluated by discrimination (Harrell's concordance index) and calibration (calibration plots and Hosmer-Lemeshow calibration test) in R. During the external validation of the nomogram, the total points for each patient in the validation cohort were calculated based on the established nomogram.

A c c e p t e d M a n u s c r i p t

The selection of the study population is illustrated in Figure 1 . A total of 372 COVID-19 patients were enrolled after admission from three centers in Guangzhou and Wuhan (Figure 1 ). All patients with non-severe COVID-19 during hospitalization were followed for more than 15 days after admission. Patients who deteriorated to severe or critical COVID-19 and patients who kept non-severe state were assigned to the severe and non-severe group, respectively. There were no significant differences in age, sex, disease types between the training cohort and validation cohorts (Table 1) Table 2 .

A total of 49 features were collected from each patient in the training cohort. and support vector machine (SVM), and evaluated their performance by the receiver operating characteristic curve (ROC) and the precision-recall curve (supplementary Figure 1 ). There were no big difference in performance of these models except for decision tree. Therefore, logistic regression model was used for further analysis owing to its high predictive power and interpretability.

The predictive nomogram that integrated 7 selected features for the incidence of severe COVID-19 in the training cohort is shown ( Figure 2C ). To evaluate clinical applicability of our risk prediction nomogram, decision curve analysis (DCA) and clinical impact curve analysis (CICA) were performed. The DCA and CICA visually showed that the nomogram had a superior overall net benefit within the wide and practical ranges of threshold probabilities and impacted patient outcomes ( Figure 2D and 2E). In Figure 3A and 3B, the calibration plot for severe illness probability showed a good agreement between the prediction by nomogram and actual observation in the training cohort and validation cohort 1, respectively.

In the training cohort, the nomogram had a significantly high AUC 0.912 (95% CI 0.846-0.978) to discriminate individuals with severe COVID-19 from non-severe COVID-19, with a sensitivity of 85.71 % and specificity of 87.58% ( Figure 3C , Table 2 ). Cutpoint R package was used to calculate optimal cutpoints by bootstraping the variability of the optimal cutpoints, which was 188.6358 for M a n u s c r i p t our nomogram (corresponding to a threshold probability of 0.190). Then patients in the validation cohorts were divided into the low group (score ≤188.6358) and the high group (score>188.6358) for further analysis. In consistent with the training cohort, in validation cohort 1, AUC was 0.853 for patients with severe COVID-19 versus non-severe COVID-19 with a sensitivity of 77.5 % and specificity of 78.4% ( Figure 3D , Table 3 ). In validation cohort 2, the sensitivity and the specificity of the nomogram were observed to be 75% and 100%, respectively.

Early identification of COVID-19 patients at risk of exacerbation to severe disease will lead to better management and optimal use of medical resources. In this research, we identified older age, higher LDH and CRP, DBIL, RDW, BUN, and lower ALB on admission correlated with higher odds of severe COVID-19. Furthermore, we developed an effective prognostic nomogram composed of 7 features, had significantly high sensitivity and specificity to distinguish individuals with severe COVID-19 from non-severe COVID-19. DCA and CICA further indicated that our nomogram conferred significantly high clinical net benefit, which is of great value for accurate individualized assessment of the incidence of severe COVID-19. NLR, a widely used marker for the assessment of system inflammation, was not identified by LASSO as an important feature instead of LDH and CRP, which are associated with the systemic inflammatory response [9] . However, LDH could predict severity of tissue damage in early stage of diseases as an auxiliary marker [10] . These might be reasons why the lasso model did not identified NLR as a more important feature. Consistent with other reports, our results indicate that patients with higher levels of inflammation at admission might be at higher risk for severe COVID-19 as well.

Interestingly, we found RDW was also an important prognostic predictor for severe COVID-19. RDW which reflects the variation in the size of RBC (red blood cells), has been reported to be significantly correlated with critical disease [11] [12] [13] but neglected in previous studies on COVID-19. It is a robust predictor of the risk of all cause patient mortality and bloodstream infection in the critically ill [12] [13] [14] [15] , including acute exacerbation of interstitial pneumonia, ARDS [11, 16] . RDW also can predict prognosis of sepsis, which was tied to poor A c c e p t e d M a n u s c r i p t COVID-19 outcomes-death [17] .

The increased RDW in COVID-19 patients may be due to the increased turnover of erythrocytes: 1) Pro-inflammatory states may be responsible for insufficient erythropoiesis with structural and functional alteration of RBC, such as decreased deformability leading to more rapid clearing of RBC. 2) Plasma cytokines such as interleukin 1 (IL-1) and tumor necrosis factor-α (TNF-α) can not only attenuate renal erythropoietin (EPO) production, but also blunt the erythroid progenitor response to EPO. In addition, INF-γ contributes to apoptosis of the erythroid progenitors and decrease the EPO receptor expression [18] . 3) RBC are dynamic reservoirs of cytokines [19] . Decreased deformability of RBC in severe illness leads to RBC lysis and release of intracellular contents into the circulation [20] , including some inflammatory cytokines. This positive feedback could greatly promote the apparent shortened RBC survival and ultimately more morphological variations in cell sizes (i.e., elevated RDW), increased inflammatory response, and lead to severe illness. RDW can be regarded as an index of enhanced patient fragility and higher vulnerability to adverse outcomes [21] . The elevated RDW may explain fatigue experienced by severe COVID-19 patients.

Our study has several strengths: first, we provide a practical quantitative prediction tool based on only 7 features which are relatively inexpensive and easily obtained from the routine blood tests. Second, to guarantee the robustness of the conclusion, we included the data from three centers with a large sample size and validation in independent cohorts. The performance of our nomogram was efficient for clinical practice.

There were some limitations in the study. First, this is a retrospective study, including 372 patients with non-severe COVID-19 on admission. ACE2, a receptor for SARS-COV-2, has been A c c e p t e d M a n u s c r i p t reported to be differentially expressed in different populations [22] . The differences in patient profiles and healthcare might have effect on the performance of nomogram in other populations outside of China. Further studies on different populations with larger patient cohorts are required to validate our findings. Second, some patients included in our study have not been discharged yet, hence their condition may change with follow-up. The final survival outcome is lacking. Third, the study has not included IgM and IgG antibodies detection. More comprehensive investigations need to be conducted to explain the characteristics of the 7 parameters included in the nomogram.

In summary, our data suggest that our nomogram can identify and predict COVID-19 patients at risk of severe disease and RDW was also valuable for this prediction. Our nomogram is especially valuable for risk stratification management, which will be helpful for alleviating insufficiency of medical resources and reducing mortality. 

The author(s) declare(s) that there is no conflict of interest regarding the publication of this paper. M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Early Prediction of Disease Progression in 2019 Novel Coronavirus Pneumonia Patients Outside Wuhan with CT and Clinical Characteristics

Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage

Prediction of criticality in patients with severe Covid-19 infection using three clinical features: a machine learning-based prognostic model with clinical data in Wuhan

Clinical characteristics of refractory COVID-19 pneumonia in

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

The prognostic value of systemic inflammatory factors in patient with metastatic gastric cancer

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

Relation between Red Cell Distribution Width and Mortality in Critically Ill Patients with Acute Respiratory Distress Syndrome

Red cell distribution width predicts out of hospital outcomes in critically ill emergency general surgery patients

Red cell distribution width (RDW) as a biomarker for respiratory failure in a pediatric ICU

Red cell distribution width and all-cause mortality in critically ill patients

RDW at Hospital Admission May Predict Prognosis of the Patient with Acute Exacerbation of Interstitial Pneumonia

Broadening of the red blood cell distribution width is associated with increased severity of illness in patients with sepsis

Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact

Red blood cells are dynamic reservoirs of cytokines

The role of red blood cells and cell-free hemoglobin in the pathogenesis of ARDS

The role of red blood cell distribution width (RDW) in cardiovascular risk assessment: useful or hype?

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Abbreviations: BMI, body mass index

WBC, white blood cell

red blood cell; NLR, neutrophil-to-lymphocyte ratio; PLR , patelet -to-lymphocyte ratio

SII, systemic immune-inflammation index; RDW-SD, red blood cell distribution width-standard deviation

RDW, red blood cell distribution width-coefficient variation

ALB, albumin; BUN, blood urea nitrogen

TBA, total bile acids

C-reactive protein; INR, international normalized ratio

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t